CY1123926T1 - Αντισωματα κατα της τρανσγλουταμινασης 2 - Google Patents
Αντισωματα κατα της τρανσγλουταμινασης 2Info
- Publication number
- CY1123926T1 CY1123926T1 CY20211100013T CY211100013T CY1123926T1 CY 1123926 T1 CY1123926 T1 CY 1123926T1 CY 20211100013 T CY20211100013 T CY 20211100013T CY 211100013 T CY211100013 T CY 211100013T CY 1123926 T1 CY1123926 T1 CY 1123926T1
- Authority
- CY
- Cyprus
- Prior art keywords
- antibodies against
- diseases
- antibodies
- transglutaminase
- core
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1075—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an enzyme
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Addiction (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
Abstract
Η εφεύρεση παρέχει αντισώματα και αντιγονοδεσμευτικά θραύσματα αυτών που δεσμεύονται επιλεκτικά σε ένα επίτοπο εντός της περιοχής πυρήνα της τρανσγλουταμινάσης τύπου 2 (TG2). Παρέχονται καινοτόμοι επίτοποι εντός του πυρήνα της TG2. Η εφεύρεση παρέχει αντισώματα αναστολής της ανθρώπινης TG2 και χρήσεις αυτών, ιδίως στην ιατρική, για παράδειγμα στη θεραπεία ή/και στη διάγνωση παθήσεων που συμπεριλαμβάνουν την κοιλιοκάκη, την ουλοποίηση, νόσους σχετιζόμενες με ίνωση, νευροεκφυλιστικές/νευρολογικές νόσους και καρκίνο.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1209096.5A GB201209096D0 (en) | 2012-05-24 | 2012-05-24 | Compounds |
| EP13730049.7A EP2855530B1 (en) | 2012-05-24 | 2013-05-24 | Anti-transglutaminase 2 antibodies |
| PCT/GB2013/051373 WO2013175229A1 (en) | 2012-05-24 | 2013-05-24 | Anti -transglutaminase 2 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1123926T1 true CY1123926T1 (el) | 2022-05-27 |
Family
ID=46546551
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20191100807T CY1121932T1 (el) | 2012-05-24 | 2019-07-29 | Αντισωματα κατα της τρανσγλουταμινασης 2 |
| CY20211100013T CY1123926T1 (el) | 2012-05-24 | 2021-01-11 | Αντισωματα κατα της τρανσγλουταμινασης 2 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20191100807T CY1121932T1 (el) | 2012-05-24 | 2019-07-29 | Αντισωματα κατα της τρανσγλουταμινασης 2 |
Country Status (39)
| Country | Link |
|---|---|
| US (3) | US10005846B2 (el) |
| EP (2) | EP2855530B1 (el) |
| JP (2) | JP6411998B2 (el) |
| KR (1) | KR102091223B1 (el) |
| CN (1) | CN104321346B (el) |
| AU (1) | AU2013265025B2 (el) |
| BR (1) | BR112014029089B1 (el) |
| CA (1) | CA2874488C (el) |
| CL (1) | CL2014003125A1 (el) |
| CO (1) | CO7151528A2 (el) |
| CY (2) | CY1121932T1 (el) |
| DK (2) | DK2855530T3 (el) |
| EA (1) | EA036810B1 (el) |
| EC (1) | ECSP14030942A (el) |
| ES (2) | ES2728856T3 (el) |
| GB (1) | GB201209096D0 (el) |
| HK (1) | HK1203974A1 (el) |
| HR (2) | HRP20191293T1 (el) |
| HU (2) | HUE045539T2 (el) |
| IL (1) | IL235369B (el) |
| IN (1) | IN2014MN02231A (el) |
| LT (2) | LT3521315T (el) |
| MA (1) | MA37670B1 (el) |
| ME (1) | ME03393B (el) |
| MX (1) | MX367517B (el) |
| MY (1) | MY185966A (el) |
| NZ (1) | NZ701424A (el) |
| PE (1) | PE20150346A1 (el) |
| PH (1) | PH12014502582B1 (el) |
| PL (2) | PL3521315T3 (el) |
| PT (2) | PT3521315T (el) |
| RS (2) | RS61286B1 (el) |
| SG (1) | SG11201407053YA (el) |
| SI (2) | SI3521315T1 (el) |
| TN (1) | TN2014000458A1 (el) |
| TR (1) | TR201906781T4 (el) |
| UA (1) | UA117657C2 (el) |
| WO (1) | WO2013175229A1 (el) |
| ZA (1) | ZA201408213B (el) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110055235A (zh) * | 2019-05-14 | 2019-07-26 | 深圳市亚辉龙生物科技股份有限公司 | 用于转谷氨酰胺酶抗体检测的抗原及其制备方法、试剂盒及检测方法 |
| GB202115127D0 (en) | 2021-10-21 | 2021-12-08 | Ucb Biopharma Sprl | Formulations |
| GB202115121D0 (en) | 2021-10-21 | 2021-12-08 | Ucb Biopharma Sprl | Formulations |
| TW202334240A (zh) | 2021-11-18 | 2023-09-01 | 比利時商Ｕｃｂ生物製藥公司 | 治療進行性慢性間質性肺部疾病之方法 |
| GB202116665D0 (en) | 2021-11-18 | 2022-01-05 | UCB Biopharma SRL | Method for the treatment of a scleroderma disease |
| GB202118010D0 (en) | 2021-12-13 | 2022-01-26 | UCB Biopharma SRL | Method for detecting and/or quantifying crosslinks formed by transglutaminases |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4912120A (en) | 1986-03-14 | 1990-03-27 | Syntex (U.S.A.) Inc. | 3,5-substituted 4,5-dihydroisoxazoles as transglutaminase inhibitors |
| AU1268192A (en) | 1991-01-04 | 1992-08-17 | Board Of Regents, The University Of Texas System | Cloning and expression of tissue transglutaminases |
| WO1998004245A1 (en) | 1996-07-25 | 1998-02-05 | The Victoria University Of Manchester | Use of transglutaminase modulators to promote wound healing |
| GB0103024D0 (en) * | 2001-02-07 | 2001-03-21 | Rsr Ltd | Assay for Autoantibodies to tissue transglutaminase |
| CA2514942A1 (en) | 2003-02-02 | 2004-08-19 | Government Of The United States Of America, As Represented By The Secret Ary, Department Of Health And Human Services | Methods and compositions for the treatment of parkinson's disease and other a-synucleinopathies |
| GB0314262D0 (en) | 2003-06-19 | 2003-07-23 | Univ Nottingham Trent | Novel compounds and methods of using the same |
| WO2006100679A2 (en) * | 2005-03-22 | 2006-09-28 | Quark Pharmaceuticals, Inc. | Recombinant antibodies against human type ii transglutaminase and uses thereof |
| WO2008063760A2 (en) | 2006-10-18 | 2008-05-29 | The University Of Texas M.D. Anderson Cancer Center | Methods for treating cancer targeting transglutaminase |
| US8614296B2 (en) * | 2008-04-24 | 2013-12-24 | Gene Techno Science Co., Ltd. | Humanized antibodies specific for amino acid sequence RGD of an extracellular matrix protein and the uses thereof |
| EP2408471B1 (en) | 2009-03-19 | 2015-06-24 | Queensland University Of Technology | Targets for growth factor signalling and methods of therapy |
| HU0900195D0 (en) * | 2009-04-01 | 2009-06-29 | Debreceni Egyetem | Diagnosis and treatment of gluten-induced autoimmune diseases |
| HU0900199D0 (en) * | 2009-04-01 | 2009-06-29 | Debreceni Egyetem | Diagnosis of gluten-induced autoimmune diseases |
| EP2579861A2 (en) | 2010-06-02 | 2013-04-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Transglutaminase 2 inhibitors for use in the prevention or treatment of rapidly progressive glomerulonephritis |
| GB2490655A (en) | 2011-04-28 | 2012-11-14 | Univ Aston | Modulators of tissue transglutaminase |
-
2012
- 2012-05-24 GB GBGB1209096.5A patent/GB201209096D0/en not_active Ceased
-
2013
- 2013-05-24 SI SI201331811T patent/SI3521315T1/sl unknown
- 2013-05-24 TR TR2019/06781T patent/TR201906781T4/tr unknown
- 2013-05-24 MX MX2014014264A patent/MX367517B/es active IP Right Grant
- 2013-05-24 LT LTEP19163818.8T patent/LT3521315T/lt unknown
- 2013-05-24 DK DK13730049.7T patent/DK2855530T3/da active
- 2013-05-24 MY MYPI2014003271A patent/MY185966A/en unknown
- 2013-05-24 US US14/402,675 patent/US10005846B2/en active Active
- 2013-05-24 SI SI201331487T patent/SI2855530T1/sl unknown
- 2013-05-24 EA EA201492162A patent/EA036810B1/ru not_active IP Right Cessation
- 2013-05-24 HU HUE13730049A patent/HUE045539T2/hu unknown
- 2013-05-24 AU AU2013265025A patent/AU2013265025B2/en active Active
- 2013-05-24 ES ES13730049T patent/ES2728856T3/es active Active
- 2013-05-24 ME MEP-2019-181A patent/ME03393B/me unknown
- 2013-05-24 MA MA37670A patent/MA37670B1/fr unknown
- 2013-05-24 IN IN2231MUN2014 patent/IN2014MN02231A/en unknown
- 2013-05-24 CA CA2874488A patent/CA2874488C/en active Active
- 2013-05-24 PL PL19163818T patent/PL3521315T3/pl unknown
- 2013-05-24 KR KR1020147036419A patent/KR102091223B1/ko active IP Right Grant
- 2013-05-24 SG SG11201407053YA patent/SG11201407053YA/en unknown
- 2013-05-24 PT PT191638188T patent/PT3521315T/pt unknown
- 2013-05-24 RS RS20210033A patent/RS61286B1/sr unknown
- 2013-05-24 DK DK19163818.8T patent/DK3521315T3/da active
- 2013-05-24 LT LTEP13730049.7T patent/LT2855530T/lt unknown
- 2013-05-24 CN CN201380026672.3A patent/CN104321346B/zh active Active
- 2013-05-24 PT PT13730049T patent/PT2855530T/pt unknown
- 2013-05-24 HU HUE19163818A patent/HUE052490T2/hu unknown
- 2013-05-24 UA UAA201413832A patent/UA117657C2/uk unknown
- 2013-05-24 RS RS20190909A patent/RS59135B1/sr unknown
- 2013-05-24 EP EP13730049.7A patent/EP2855530B1/en active Active
- 2013-05-24 PL PL13730049T patent/PL2855530T3/pl unknown
- 2013-05-24 EP EP19163818.8A patent/EP3521315B1/en active Active
- 2013-05-24 BR BR112014029089-0A patent/BR112014029089B1/pt active IP Right Grant
- 2013-05-24 WO PCT/GB2013/051373 patent/WO2013175229A1/en active Application Filing
- 2013-05-24 JP JP2015513275A patent/JP6411998B2/ja active Active
- 2013-05-24 PE PE2014002040A patent/PE20150346A1/es active IP Right Grant
- 2013-05-24 ES ES19163818T patent/ES2835383T3/es active Active
- 2013-05-24 NZ NZ701424A patent/NZ701424A/en unknown
-
2014
- 2014-10-28 TN TN2014000458A patent/TN2014000458A1/fr unknown
- 2014-10-28 IL IL235369A patent/IL235369B/en active IP Right Grant
- 2014-11-10 ZA ZA2014/08213A patent/ZA201408213B/en unknown
- 2014-11-18 CL CL2014003125A patent/CL2014003125A1/es unknown
- 2014-11-19 PH PH12014502582A patent/PH12014502582B1/en unknown
- 2014-12-12 EC ECIEPI201430942A patent/ECSP14030942A/es unknown
- 2014-12-23 CO CO14281628A patent/CO7151528A2/es unknown
-
2015
- 2015-05-11 HK HK15104401.8A patent/HK1203974A1/xx unknown
-
2018
- 2018-05-23 US US15/987,611 patent/US10961319B2/en active Active
- 2018-05-30 JP JP2018104139A patent/JP2018166510A/ja active Pending
-
2019
- 2019-07-18 HR HRP20191293TT patent/HRP20191293T1/hr unknown
- 2019-07-29 CY CY20191100807T patent/CY1121932T1/el unknown
-
2020
- 2020-12-14 US US17/121,541 patent/US11718686B2/en active Active
- 2020-12-23 HR HRP20202059TT patent/HRP20202059T1/hr unknown
-
2021
- 2021-01-11 CY CY20211100013T patent/CY1123926T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123926T1 (el) | Αντισωματα κατα της τρανσγλουταμινασης 2 | |
| CY1122458T1 (el) | Αντισωματα αντι-n3pglu αμυλοειδους βητα πεπτιδιου και χρησεις αυτων | |
| CY1122490T1 (el) | Αντισωματα κατα του ανθρωπινου cd38 | |
| CY1121148T1 (el) | Παραγοντες συνδεσης vegf/dll4 και χρησεις αυτων | |
| CY1122245T1 (el) | Pd-1 αντισωμα, θραυσμα δεσμευσης αντιγονου αυτου, και ιατρικη εφαρμογη αυτου | |
| CY1122840T1 (el) | Ανθρωποποιημενα ή χιμαιρικα αντισωματα cd3 | |
| MD3328888T2 (ro) | Anticorpi anti-PSMA, molecule de legare a antigenelor bispecifice care leagă PSMA și CD3 și utilizările acestora | |
| EA201691858A1 (ru) | Композиции антител для лечения опухолей | |
| CY1118369T1 (el) | Αντισωματα εναντι cd38 για την θεραπεια πολλαπλου μυελωματος | |
| EA201890145A1 (ru) | Антитела к фактору xi и способы их применения | |
| UA109633C2 (uk) | Антитіло людини проти тканинного фактора | |
| EA201790404A1 (ru) | Макропиноцитозирующие человеческие анти-cd46 антитела и таргетная терапия рака | |
| AR092818A1 (es) | Anticuerpo tau humanizado | |
| BR112018068678A2 (pt) | anticorpos anti-mica | |
| GEP20217263B (en) | Anti-cd27 antibodies | |
| UY35042A (es) | Anticuerpos anti-cd3, moléculas de unión a antígeno biespecíficas que se unen a cd3 y cd20, y usos de los mismos. | |
| UA115439C2 (uk) | Гуманізоване антитіло, яке розпізнає альфа-синуклеїн | |
| EA201790305A1 (ru) | КОМБИНИРОВАННАЯ ТЕРАПИЯ БОЛЕЗНИ АЛЬЦГЕЙМЕРА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ МОНОКЛОНАЛЬНЫХ АНТИТЕЛ К N3pGlu АБЕТА И ИНГИБИТОРА BACE | |
| EA201590187A1 (ru) | Моноклональные антитела для применения в диагностике и терапии злокачественных опухолей и аутоиммунного заболевания | |
| EA201691836A1 (ru) | Антитела к mcam и соответствующие способы их применения | |
| CY1120468T1 (el) | Εξανθρωπισμενα αντισωματα il-25 | |
| MX2015008534A (es) | COMPOSICIONES DE ANTICUERPO ANTI-INTEGRINA ß1 Y METODOS DE USO DE LAS MISMAS. | |
| MX2015008117A (es) | Anticuerpos anti-h7cr. | |
| EA201890347A1 (ru) | Антитела и исследования для обнаружения cd37 | |
| CL2019000702A1 (es) | Anticuerpos anti-gm-csf y usos de los mismos. |